CAR-T Cell Therapy for Treatment-Resistant Lupus
Treatments studied
Part of Immune system & allergy, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This study tests a new type of immune cell therapy (CAR-T cells) designed to target and reduce the immune cells driving lupus in patients whose disease hasn't responded to standard treatments. Researchers will first identify which specific immune cells are causing your lupus, then engineer your own immune cells to fight them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–70 years old
- Confirmed diagnosis of systemic lupus erythematosus (SLE) that meets medical classification criteria
- Active, severe lupus that hasn't improved despite at least 2 different standard treatments (including immunosuppressants or biologics)
- Blood tests showing specific immune cells (CD19+ B cells or BCMA+ plasma cells) that can be targeted
- If you have lupus kidney disease, a kidney biopsy within the past 2 years confirming it, or clinical confirmation if biopsy is unsafe
- Adequate organ function (liver, kidney, heart, and blood counts) to tolerate the therapy
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized treatment called CD19 CAR T-cell therapy for people with severe lupus that hasn't improved with standard treatments. It uses your own immune cells to target and destroy the faulty cells causing lupus symptoms.
This trial tests a new treatment using your own immune cells (called CAR-T cells) that are modified to target two proteins (CD19 and BCMA) on lupus cells. It is for people with lupus nephritis (kidney inflammation) that has not improved after trying multiple standard treatments.
This trial tests a new type of CAR T cell therapy for people with active lupus that has not responded to other treatments. It uses specially engineered cells to target and eliminate certain immune cells that are causing the disease, with the goal of reducing symptoms and preventing flare-ups.
This trial tests a new type of cell therapy (CAR-T cells) that targets two proteins on immune cells (CD19 and BCMA) to treat lupus that hasn't responded to standard treatments. It may help people with moderate to severe lupus by reducing disease activity without ongoing medication.
This trial tests a treatment called CD19/BCMA CAR-T for people with lupus (SLE) that has not improved with standard treatments. The therapy uses your own immune cells, modified to target and calm overactive immune cells, aiming to reduce disease activity.
This trial tests a treatment where your own immune cells are modified to attack and destroy lupus-causing B cells. It's for people with lupus (SLE) that hasn't improved with standard treatments.
Hear when a new Refractory Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.